Movers and Shakers Top Gaining and Losing Stocks Today

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  17 Feb 2026
 

•   AREB  
   
  0.00%
•   CMPS  
   
  0.00%
•   ETOR  
   
  0.00%
•   MASI  
   
  0.00%
•   OCUL  
   
  0.00%

$MASI is the clear headline driver after Danaher Corporation agreed to acquire Masimo Corporation in a deal valued at roughly $9.9 billion. The $180 per share cash offer represents a sizable premium to the prior close, pushing shares up 34% to $174.69 on volume nearing 15 million versus an average of just 742K. This is classic merger-arb price discovery: the stock is trading at a modest discount to the takeout price, reflecting deal risk and expected timing. Governance changes driven by activist pressure had already put Masimo in play; today’s move formalizes that strategic reset.

$CMPS surged 31% to $7.63 after Compass Pathways reported positive Phase 3 data for its psilocybin-based treatment in severe depression. Volume exploded to 34.7 million shares against a 1.4 million average, signaling both short covering and fresh speculative positioning. Late-stage clinical validation meaningfully derisks the regulatory pathway, though traders should expect volatility as the market recalibrates peak sales assumptions and potential commercialization timelines.

$ZIM rallied 25% to $27.85 following news that Hapag-Lloyd agreed to acquire ZIM Integrated Shipping Services for $35 per share in cash. The transaction implies a substantial premium to recent trading levels and ignited 39.5 million shares of turnover versus a 3.3 million average. Like MASI, this is event-driven repricing; the remaining spread reflects regulatory approvals and cross-border execution risk in a cyclical shipping sector still navigating rate normalization.

$ETOR climbed 20% to $33.07 after eToro Group Ltd. posted a Q4 earnings beat and highlighted strong full-year metrics. Adjusted EPS topped expectations, and management commentary around user growth and trading activity reinforced operating leverage in a more active retail environment. Volume of 5 million shares, over 3x normal levels, suggests institutions are reassessing forward revenue durability amid improved engagement trends.

$OEC dropped 19% to $5.74 after Orion Engineered Carbons reported a non-GAAP EPS miss despite a revenue beat. Margin pressure appears to be the focal point, with the earnings shortfall outweighing top-line strength. At 1.8 million shares traded versus a 620K average, the move reflects a reset in profitability expectations rather than a liquidity vacuum.

$OCUL fell 21% to $6.99 even after Ocular Therapeutix announced that AXPAXLI met its superiority endpoint in a Phase 3 wet AMD trial. The disconnect between positive clinical data and price action on massive 51 million share volume suggests concerns about competitive positioning, durability of effect, or commercial economics. This looks more like "sell the news" behavior after a pre-run into data.

$UOKA is down 22% to $0.30, extending a five-day losing streak. Volume at 2.4 million shares trails its 5.3 million average, pointing to fading participation rather than panic liquidation. In sub-dollar names, persistent drift lower often signals capital rotation away from speculative microcaps rather than a single catalyst.

$XTKG slid 31% to $0.12 despite filing a Nasdaq appeal to continue listing. At 12.1 million shares traded versus a 49 million average, liquidity is thinning as the market discounts prolonged compliance uncertainty. Appeals can buy time, but they rarely reverse underlying structural issues without fundamental improvement.

$AREB plunged 41% to $0.18, marking a tenth consecutive down session. With 8.7 million shares traded against a 2.2 million average, this resembles capitulation in a thinly capitalized name. Extended multi-day selloffs of this magnitude typically reflect a combination of technical breakdown and limited institutional sponsorship.

View All Headlines